A three-gene signature and clinical outcome in esophageal squamous cell carcinoma

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages E569-E577

  Sun, Ling Ling ^a,b   Wu, Jian Yi ^a   Wu, Zhi Yong ^c   Shen, Jin Hui ^c   Xu, Xiu E ^a   Chen, Bo ^a   Wang, Shao Hong ^c   Li, En Min ^a   Xu, Li Yan ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

^c SHANTOU CENTRAL HOSPITAL   (China)

Author keywords

Esophageal squamous cell carcinoma; Gene prognostic signature; Histone demethylase; Histopathology

Indexed keywords

KRUPPEL LIKE FACTOR 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN MDM2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ADULT; ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GASC1 GENE; GENE; GENE EXPRESSION; GENETIC RISK; HUMAN; HUMAN TISSUE; KLF4 GENE; MAJOR CLINICAL STUDY; MALE; MDM2 GENE; NANOG GENE; ONCOGENE MYC; OVERALL SURVIVAL; PPARG GENE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SOX2 GENE; TUMOR GENE;

EID: 84964285764     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29211     Document Type: Article

References (43)

1. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
3. Katlic MR, Wilkins EW, Jr, Grillo HC. Three decades of treatment of esophageal squamous carcinoma at the Massachusetts General Hospital. J Thorac Cardiovasc Surg 1990;99:929-38.
4. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52.
5. Tachibana M, Kinugasa S, Hirahara N, et al. Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur J Cardiothorac Surg 2008;34:427-31.
6. Liu G, Bollig-Fischer A, Kreike B, et al. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 2009;28:4491-500.
7. Zhou W, Chen H, Zhang L. The PcG protein hPc2 interacts with the N-terminus of histone demethylase JARID1B and acts as a transcriptional co-repressor. BMB Rep 2009;42:154-59.
8. Cloos PA, Christensen J, Agger K, et al. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006;442:307-11.
9. Suikki HE, Kujala PM, Tammela TL, et al. Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate 2010;70:889-98.
10. Italiano A, Attias R, Aurias A, et al. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet Cytogenet 2006;167:122-30.
11. Hélias C, Struski S, Gervais C, et al. Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer Genet Cytogenet 2008;180:51-5.
12. Wang J, Zhang M, Zhang Y, et al. The histone demethylase JMJD2C is stage-specifically expressed in preimplantation mouse embryos and is required for embryonic development. Biol Reprod 2010;82:105-11.
13. Lizcano F, Romero C, Vargas D. Regulation of adipogenesis by nuclear receptor PPARγ is modulated by the histone demethylase JMJD2C. Genet Mol Biol 2011;34:19-24.
14. Ishimura A, Terashima M, Kimura H, et al. Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene. Biochem Biophys Res Commun 2009;389:366-71.
15. Sun LL, Holowatyj A, Xu XE, et al. Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma. Am J Cancer Res 2013;3:509-17.
16. Yang ZQ, Imoto I, Fukuda Y, et al. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res 2000;60:4735-9.
17. Yang ZQ, Imoto I, Pimkhaokham A, et al. A novel amplicon at 9p23-24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB. Jpn J Cancer Res 2001;92:423-8.
18. Hu N, Wang C, Hu Y, et al. Genome-wide association study in esophageal cancer using Gene-Chip mapping 10K array. Cancer Res 2005;65: 2542-6.
19. Ragvin A, Valvatne H, Erdal S, et al. Nucleosome binding by the bromodomain and PHD finger of the transcriptional cofactor p300. J Mol Biol 2004;337:773-88.
20. Zhang FR, Tao LH, Shen ZY, et al. Fascin expression in human embryonic, fetal, and normal adult tissue. J Histochem Cytochem 2008;56:193-9.
21. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9.
22. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
23. Rayburn E, Zhang R, He J, et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005;5:27-41.
24. Jiang Y, Zou L, Zhang C, et al. PPARgamma and Wnt/beta-Catenin pathway in human breast cancer: expression pattern, molecular interaction and clinical/prognostic correlations. J Cancer Res Clin Oncol 2009;135:1551-9.
25. Ogino S, Shima K, Baba Y, et al. Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPAR-gamma) is associated with good prognosis. Gastroenterology 2009;136:1242-50.
26. Theocharis S, Klijanienko J, Giaginis C, et al. Peroxisome proliferator-activated receptor-γ in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. J Cancer Res Clin Oncol 2011;137:251-9.
27. Nakamura Y, Suzuki T, Sugawara A, et al. Peroxisome proliferator-activated receptor gamma in human prostate carcinoma. Pathol Int 2009;59:288-93.
28. Giaginis C, Katsamangou E, Tsourouflis G, et al. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. Med Sci Monit 2009;15:BR148-56.
29. Ezeh UI, Turek PJ, Reijo RA, et al. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005;104:2255-65.
30. Alldridge L, Metodieva G, Greenwood C, et al. Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry. J Proteome Res 2008;7:1458-69.
31. Ye F, Zhou C, Cheng Q, et al. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 2008;8:108.
32. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008;14:4085-95.
33. Bussolati B, Bruno S, Grange C, et al. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008;22:3696-705.
34. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-20.
35. Liu TM, Wu YN, Guo XM, et al. Effects of ectopic Nanog and Oct4 overexpression on mesenchymal stem cells. Stem Cells Dev 2009;18:1013-22.
36. Zhang J, Wang X, Chen B, et al. Expression of Nanog gene promotes NIH3T3 cell proliferation. Biochem Biophys Res Commun 2005;338:1098-102.
37. Lin YL, Han ZB, Xiong FY, et al. Malignant transformation of 293 cells induced by ectopic expression of human Nanog. Mol Cell Biochem 2011;351:109-16.
38. McClatchey AI. Merlin and ERM proteins: unappreciated roles in cancer development? Nat Rev Cancer 2003;3:877-83.
39. Neumann J, Bahr F, Horst D, et al. SOX2 expression correlates with lymph-node metastases and distant spread in right-sided colon cancer. BMC Cancer 2011;11:518.
40. Rapp UR, Korn C, Ceteci F, et al. Myc is a metastasis gene for non-small-cell lung cancer. Plos One 2009;4:e6029.
41. Tiwari N, Meyer-Schaller N, Arnold P, et al. Correction: Klf4 Is a Transcriptional Regulator of Genes Critical for EMT, Including Jnk1 (Mapk8). PLoS One 2013;8:e57329.
42. Luo W, Chang R, Zhong J, et al. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci USA 2012;109:E3367-76.
43. Yamamoto S, Tateishi K, Kudo Y, et al. Histone demethylase KDM4C regulates sphere formation by mediating the crosstalk between Wnt and Notch pathways in colonic cancer cells. Carcinogenesis 2013;34:2380-8.